Our Portfolio

Icahn School of Medicine at Mount Sinai

Ana Pereira, MD | New York, United States

Project Overview

  • Academic/Nonprofit Organization Type
  • $106,000 Funding Amount
  • 3/1/18 — 9/1/20 Project Duration
  • Clinical Program
  • Synaptic Activity and Neurotransmitters Target
  • Clinical Phase 2 Therapeutic Stage
  • Closed Status

Icahn School of Medicine at Mount Sinai

Ana Pereira, MD | New York, United States

Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Cognitive Impairment - Expansion to an additional clinical site

No summary available

GET IN TOUCH